JAK inhibitor

dynamic arrows moving up
Biotech

Priovant will move brepocitinib to phase 3 after midstage win

Priovant has presented promising results for potential blockbuster brepocitinib in a rare skin disorder, cutaneous sarcoidosis.
Kevin Dunleavy Feb 6, 2026 7:00am
pipeline valve pipe flow water tap

Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash

Nov 4, 2025 9:40am
An arrow incrementally going up stairs before pointing straight up Blue background

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

Sep 17, 2025 7:00am
Photo of a final puzzle piece about to fit into a puzzle

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor

Jun 23, 2025 9:47am
business targets illustration

Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win

May 21, 2025 6:25am
positive negative up down good bad mixed

Incyte posts phase 3 skin condition wins but details disappoint

Mar 17, 2025 8:12am